Who
Arie Belldegrun
Director
Company insider
Files Form 4 as: Director, UroGen Pharma; Director and 10% owner, Allogene Therapeutics; Director, Kronos Bio; Director, Ginkgo Bioworks Holdings; Chairman, President and CEO, Kite Pharma; Director, Arno Therapeutics; Director, Capricor Therapeutics; Director and 10% owner, Cougar Biotechnology.
In numbers
- Trades disclosed
- 248
- Buys
- 18
- Sells
- 2
- Bought
- $21.2M
- Sold
- $4.9M
- Companies
- 10
- Companies where not an officer
- 9
- First trade
- 11 Jan 2006
- Last trade
- 22 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jun 2026filed 24 Jun 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —929,913 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —263,033 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —929,913 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —263,033 at $0.00 | filing |
| 26 Aug 2025filed 27 Aug 2025 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Biooption or derivative | SEC FORM 4 Code D | —20,600 at $0.00 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Biooption or derivative | SEC FORM 4 Code D | —34,000 at $0.00 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Biooption or derivative | SEC FORM 4 Code D | —34,000 at $0.00 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Biooption or derivative | SEC FORM 4 Code D | —34,000 at $0.00 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Bio | SEC FORM 4 Code U | $1.6M2,765,314 at $0.57 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Bio | SEC FORM 4 Code U | $387K679,575 at $0.57 | filing |
| 24 Jan 2025filed 28 Jan 2025 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,307,927 at $0.00 | filing |
| 24 Jan 2025filed 28 Jan 2025 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —369,957 at $0.00 | filing |
| 6 Aug 2024filed 8 Aug 2024 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 25 Jun 2024filed 26 Jun 2024 | Kronos Biooption or derivative | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | DNA Ginkgo Bioworks Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —432,900 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | DNA Ginkgo Bioworks Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —571,428 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | DNA Ginkgo Bioworks Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | —105,263 | filing |
News
Comparing eXoZymes (NASDAQ:EXOZ) and Allogene Therapeutics (NASDAQ:ALLO)ALLO · dailypolitical.com · 16 Oct 2026Head to Head Comparison: Generate Biomedicines (NASDAQ:GENB) vs. Allogene Therapeutics (NASDAQ:ALLO)ALLO · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Arie Belldegrun; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.